CASI Pharmaceuticals To Hold Business Update Conference Call And Webcast On January 6th

ROCKVILLE, Md., Dec. 23, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary commercial focus on China, announces it will host a conference call at 4:15 p.m. Eastern time on January 6, 2015. Dr. Ken K. Ren, Chief Executive Officer, will host the call and will provide a business update and discuss plans for the coming year.  Cynthia W. Hu, Chief Operating Officer, and Sara B. Capitelli, Vice President, Finance, will also participate in the call.

CASI Pharmaceuticals logo

Conference Call Details:

Date: Tuesday, January 6, 2015            
Time: 4:15 p.m. ET    
U.S. toll free: (888) 803-5993
International:  (706) 634-5454
Conference ID: 56451104    

Please join the conference call at least 10 minutes early to ensure the line is connected. A live webcast of the conference call will be accessible from the investor relations section of the CASI Pharmaceuticals website. The link will be available for 90 days. In addition, a telephone replay will be available from 7:15 p.m. eastern time on January 6th through midnight eastern time on January 26th by calling 855-859-2056 in the U.S. and 404-537-3406 for International access.  As an accommodation to interested investors who may not be able to ask questions live, emailed questions may be submitted in advance of the call to IR@casipharmaceuticals.com.  Management will attempt to answer as many questions as possible and as appropriate during the Q&A portion of the call. Please submit questions by 5:00 p.m. eastern time on January 5th.

About CASI Pharmaceuticals, Inc.

CASI is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary commercial focus on China. CASI's product pipeline includes exclusive rights to ZEVALIN® (ibritumomab tiuxetan), MARQIBO® (vinCRIStine sulfate LIPOSOME injection) and Captisol-EnabledTM (propylene glycol-free) melphalan (CE melphalan) for greater China (including Taiwan, Hong Kong and Macau). CASI's development pipeline also includes its proprietary drug candidate ENMD-2076, a selective angiogenic kinase inhibitor currently in multiple Phase 2 oncology studies, and 2ME2 (2-methoxyestradial) currently under reformulation development. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in the Company's filings with the U.S. Securities and Exchange Commission. In addition, CASI will be updating its Corporate Presentation to be available on its website at www.casipharmaceuticals.com/investor-relations.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.  Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility in the market price of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest stockholders that differ from our other stockholders; and the risk of substantial dilution of existing stockholders in future stock issuances.  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

ZEVALIN® and MARQIBO® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates.  Captisol-Enabled is the trademark property of its owner.

 

COMPANY CONTACT:

CASI Pharmaceuticals, Inc.

240.864.2643

ir@casipharmaceuticals.com        

INVESTOR CONTACT:

LHA

Kim Sutton Golodetz

212.838.3777

kgolodetz@lhai.com            

 

Logo - http://photos.prnewswire.com/prnh/20140706/124566

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-hold-business-update-conference-call-and-webcast-on-january-6th-300013281.html

SOURCE CASI Pharmaceuticals, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news